Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases

Cancer Research

Volumn 70, Issue 18, 2010, Pages 7063-7072

  Endo Munoz, Liliana ^a   Cumming, Andrew ^a   Rickwood, Danny ^a   Wilson, Danielle ^a   Cueva, Claudia ^a   Ng, Charlotte ^a   Strutton, Geoffrey ^b   Cassady, A Ian ^a   Evdokiou, Andreas ^d   Sommerville, Scott ^b,c   Dickinson, Ian ^b,c   Guminski, Alexander ^b   Saunders, Nicholas A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c WESLEY HOSPITAL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; FULVESTRANT; TARTRATE RESISTANT ACID PHOSPHATASE 5; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; ACID PHOSPHATASE; ISOENZYME; TARTRATE-RESISTANT ACID PHOSPHATASE;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE BIOPSY; CARCINOGENESIS; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGED; ANIMAL; BAGG ALBINO MOUSE; BIOPSY; BIOSYNTHESIS; BONE TUMOR; CHILD; ENZYMOLOGY; LUNG TUMOR; MIDDLE AGED; MOUSE; PATHOLOGY; SECONDARY; YOUNG ADULT;

ACID PHOSPHATASE; ADOLESCENT; ADULT; AGED; ANIMALS; BIOPSY; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; OSTEOCLASTS; OSTEOSARCOMA; YOUNG ADULT;

EID: 77956913447     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4291     Document Type: Article

References (53)

1. Bielack SS, Kempf-Bielack B, Heise U, Schwenzer D, Winkler K. Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group. J Clin Oncol 1999;17:1164-74.
2. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9:422-41.
3. Bacci G, Mercuri M, Briccoli A, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer 1997; 79:245-54.
4. Udagawa N, Takahashi N, Akatsu T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A 1990;87:7260-4.
5. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289: 1504-8.
6. Halleen JM. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res 2003;23:1027-9.
7. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-14.
8. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-36.
9. Terpos E, de la Fuente J, Szydlo R, et al. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 2003;106:455-7.
10. Schneider A, Kalikin LM, Mattos AC, et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005;146:1727-36.
11. Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 2008;27:41-55.
12. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140:4451-8.
13. Lyubimova NV, Pashkov MV, Tyulyandin SA, Gol'dberg VE, Kushlinskii NE. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer. Bull Exp Biol Med 2004;138:77-9.
14. Chao TY, Yu JC, Ku CH, et al. Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients. Clin Cancer Res 2005;11:544-50.
15. Harvey HA, Cream LR. Biology of bone metastases: causes and consequences. Clin Breast Cancer 2007;7 Suppl 1:S7-13.
16. Arguello F, Baggs RB, Graves BT, Harwell SE, Cohen HJ, Frantz CN. Effect of IL-1 on experimental bone/bone-marrow metastases. Int J Cancer 1992;52:802-7.
17. Shimamura T, Amizuka N, Li M, et al. Histological observations on the microenvironment of osteolytic bone metastasis by breast carcinoma cell line. Biomed Res 2005;26:159-72.
18. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
19. Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002;20:850-6.
20. Guise TA. The vicious cycle of bone metastases. J Musculoskelet Neuronal Interact 2002;2:570-2.
21. Thomson BM, Mundy GR, Chambers TJ. Tumor necrosis factors α and β induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol 1987;138:775-9.
22. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
23. Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, Evdokiou A. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res 2009;15:3451-61.
24. Evdokiou A, Labrinidis A, Bouralexis S, Hay S, Findlay DM. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 2003;33:216-28.
25. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and computational biology solutions using R and Bioconductor. New York (NY): Springer; 2005, p. 397-420.
26. Smyth GK, Speed TP. Normalization of cDNA microarray data. Methods 2003;31:265-73.
27. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:1-25.
28. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002;30:207-10.
29. Takahashi N, Yamana H, Yoshiki S, et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 1988;122:1373-82.
30. Ek-Rylander B, Barkhem T, Ljusberg J, Ohman L, Andersson KK, Andersson G. Comparative studies of rat recombinant purple acid phosphatase and bone tartrate-resistant acid phosphatase. Biochem J 1997;321:305-11.
31. Luu HH, Kang Q, Park JK, et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 2005;22:319-29.
32. Endo-Munoz LB, Cumming A, Sommerville S, Dickinson I, Saunders NA. Osteosarcoma is characterized by reduced expression of markers of impaired osteoclastogenesis and antigen presentation compared with normal bone. Br J Cancer 2010;103:73-81.
33. Bar-Shavit Z. The osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell. J Cell Biochem 2007;102:1130-9.
34. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
35. Efstratiadis T, Moss DW. Tartrate-resistant acid phosphatase in human alveolar macrophages. Enzyme 1985;34:140-3.
36. Micklem K, Rigney E, Cordell J, et al. A human macrophage-associated antigen (CD68) detected by six different monoclonal antibodies. Br J Haematol 1989;73:6-11.
37. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999;256:449-55.
38. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
39. Yao GQ, Sun BH, Weir EC, Insogna KL. A role for cell-surface CSF-1 in osteoblast-mediated osteoclastogenesis. Calcif Tissue Int 2002; 70:339-46.
40. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44.
41. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 2000;89: 817-25.
42. Denger S, Reid G, Gannon F. Expression of the estrogen receptor during differentiation of human osteoclasts. Steroids 2008;73: 765-74.
43. Riggs BL, Khosla S, Melton LJ III. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998;13:763-73.
44. Sahai E. Illuminating the metastatic process. Nat Rev Cancer 2007;7: 737-49.
45. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
46. Bernards R, Weinberg RA. A progression puzzle. Nature 2002; 418:823.
47. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
48. Weigelt B, Hu Z, He X, et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005;65:9155-8.
49. Maris JM, Courtright J, Houghton PJ, et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:581-7.
50. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000; 6:572-7.
51. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2:563-72.
52. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
53. Chirgwin JM, Guise TA. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. J Cell Biochem 2007;102:1333-42.